# US 6,727,102 B1 · Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,102 B1
- Document ID: US6727102B1
- Status: Granted
- Kind: B1
- Application number: 09/446,259
- Filed: 1999-12-20
- Granted: 2004-04-27
- Earliest claimed: 1999-12-20
- Assignees: Leuven Research & Development VZW
- Inventors: Paul Noel Holvoet; Désiré José Collen
- Web page: https://patentgrep.com/patent/US6727102B1

## CPC

- G01N 33/96: involving blood or serum control standard
- C07K 16/18: against material from animals or humans
- G01N 33/92: involving lipids, e.g. cholesterol {, lipoproteins, or their receptors (steroid hormones G01N33/743)}
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2800/044: Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
- G01N 2800/323: Arteriosclerosis, Stenosis
- Y10T 436/104165: Lipid, cholesterol, or triglyceride standard or control
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Immunoassays for malondialdehyde-modified low density lipprotein (MDA-modified LDL) and oxidized low density lipprotein (OxLDL), monoclonal antibodies (and the cell lines for them) for use in the assays, and a storage-stable standard (which may be used as a calibrator and/or control) are disclosed. MDA-modified LDL and OxLDL are implicated in atherosclerosis and its etiology.

## Claims

### Claim 1

An immunological assay for the detection and/or quantification of human MDA-modified LDL (malondialdehyde-modified low density lipoprotein) and human OxLDL (oxidized low density lipoprotein) in a sample derived from the body fluids or tissues of a human being, said assay comprising:
(a) contacting the sample with a first antibody that has high affinity for human MDA-modified LDL and human OxLDL wherein the first antibody is the monoclonal antibody mAb-4E6 produced by hybridoma Hyb4E6 deposited at the BCCM (Belgian Coordinated Collections of Microorganisms) under deposit accession number LMBP 1660 CB on Apr. 24, 1997; and
(b) thereafter visualizing and/or quantifying a binding reaction between the first antibody and the MDA-modified LDL and OxLDL present in the sample;
wherein the MDA-modified LDL and OxLDL for which the first antibody has high affinity contain at least 60 substituted lysine moieties per apo B-100 (apolipoprotein B-100) moiety.

### Claim 2 (depends on 1)

The assay of claim 1 in which the MDA-modified LDL and OxLDL for which the first antibody has high affinity contain at least about 90 substituted lysine moieties per apo B-100 moiety.

### Claim 3 (depends on 1)

The assay of claim 1 in which the MDA-modified LDL and OxLDL for which the first antibody has high affinity contain at least about 120 substituted lysine moieties per apo B-100 moiety.

### Claim 4 (depends on 1)

The assay of claim 1 in which the MDA-modified LDL and OxLDL for which the first antibody has high affinity contain at least about 210 substituted lysine moieties per apo B-100 moiety.

### Claim 5 (depends on 1)

The assay of claim 1 in which the MDA-modified LDL and OxLDL for which the first antibody has high affinity contain at least about 240 substituted lysine moieties per apo B-100 moiety.

### Claim 6 (depends on 1)

The assay of claim 1 which is a competitive assay.

### Claim 7 (depends on 6)

The competitive assay of claim 6 in which MDA-modified LDL and/or OxLDL are bound to a substrate, comprising contacting the sample and the first antibody with the substrate having bound to it MDA-modified LDL and OxLDL.

### Claim 8 (depends on 1)

The assay of claim 1 which is a sandwich assay in which the first antibody is bound to a substrate, comprising contacting the sample with the substrate having bound to it the first antibody.

### Claim 9 (depends on 8)

The assay of claim 8 in which a second antibody is used and the second antibody has high affinity for human MDA-modified LDL and human OxLDL.

### Claim 10 (depends on 9)

The assay of claim 9 in which the second antibody has high affinity for human native LDL.

### Claim 11 (depends on 1)

The assay of claim 1 which is an immunohistochemical assay in which the sample is a tissue sample and it is contacted with the first antibody.

### Claim 12 (depends on 1)

The assay of claim 1 in which the affinity constant of the first antibody for MDA-modified LDL and for OxLDL is at least about 1×1010 M−1.

### Claim 13 (depends on 1)

The assay of claim 1 in which the first antibody has low affinity for human native LDL.

### Claim 14 (depends on 3)

The assay of claim 3 in which the affinity constant of the first antibody for human native LDL is less than about 1×106 M−1.

### Claim 15 (depends on 9)

The assay of claim 9 in which the affinity constant of the second antibody for MDA-modified LDL and for OxLDL is at least about 1×1010 M−1.

### Claim 16 (depends on 15)

The assay of claim 15 in which the affinity constant of the second antibody for human native LDL is at least about 1×109 M−1.

### Claim 17 (depends on 16)

The assay of claim 16 in which the second antibody is the monoclonal antibody mAb-8A2 produced by hybridoma Hyb8A2 deposited at the BCCM under deposit accession number LMBP 1661 CB on Apr. 24, 1997.

### Claim 18 (depends on 1)

The assay of claim 1 in which the sample is derived from the body fluids of a human being.

### Claim 19 (depends on 1)

The assay of claim 1 in which at least one antibody is capable of detecting 0.02 mg/dl of human MDA-modified LDL and human OxLDL in undiluted human plasma.
